Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

RemeGen Publishes Data Showing Telitacicept Effective for Sjögren's Syndrome

publication date: Jul 28, 2023

RemeGen reported that data from a Phase II trial published in Rheumatology, a medical journal, showed telitacicept was effective in treating Primary Sjögren's Syndrome. Telitacicept is a novel fully human TACI-Fc fusion protein that shows promise in inhibiting B cell maturation and reducing autoantibody production. As RemeGen’s lead drug, telitacicept is in clinical trials for seven autoimmune diseases. Two years ago, the drug was approved in China for another autoimmune disease, systemic lupus erythematosus. RemeGen, a Yantai biopharma, has also developed disitamab vedotin, an ADC drug, which was approved to treat gastric cancer in 2021. More details....

Stock Symbols: (HK: 9995; SHA: 688331)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital